ASX:CYP

Stock Analysis Report

Executive Summary

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Snowflake

Fundamentals

Exceptional growth potential with excellent balance sheet.

Share Price & News

How has Cynata Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.2%

CYP

-1.0%

AU Biotechs

-1.0%

AU Market


1 Year Return

16.7%

CYP

46.2%

AU Biotechs

16.2%

AU Market

Return vs Industry: CYP underperformed the Australian Biotechs industry which returned 46.2% over the past year.

Return vs Market: CYP matched the Australian Market which returned 16.2% over the past year.


Shareholder returns

CYPIndustryMarket
7 Day-7.2%-1.0%-1.0%
30 Day1.2%5.7%-0.2%
90 Day-25.8%12.4%2.2%
1 Year16.7%16.7%47.9%46.2%21.9%16.2%
3 Year75.0%75.0%174.3%164.4%36.3%17.7%
5 Year206.3%206.3%222.1%201.2%52.7%18.3%

Price Volatility Vs. Market

How volatile is Cynata Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cynata Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CYP (A$1.23) is trading below our estimate of fair value (A$8.95)

Significantly Below Fair Value: CYP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CYP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CYP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYP is overvalued based on its PB Ratio (11.4x) compared to the AU Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Cynata Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

94.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: CYP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CYP's is expected to become profitable in the next 3 years.

Revenue vs Market: CYP's revenue (64% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: CYP's revenue (64% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CYP's Return on Equity is forecast to be very high in 3 years time (82.9%).


Next Steps

Past Performance

How has Cynata Therapeutics performed over the past 5 years?

-15.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYP has high quality earnings.

Growing Profit Margin: CYP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYP is unprofitable, and losses have increased over the past 5 years at a rate of -15.8% per year.

Accelerating Growth: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.5%).


Return on Equity

High ROE: CYP has a negative Return on Equity (-77.22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cynata Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CYP's short term assets (A$7.3M) exceeds its short term liabilities (A$1.3M)

Long Term Liabilities: CYP has no long term liabilities


Debt to Equity History and Analysis

Debt Level: CYP is debt free.

Reducing Debt: CYP had no debt 5 years ago.


Balance Sheet

Inventory Level: CYP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CYP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CYP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CYP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Cynata Therapeutics's salary, the management and board of directors tenure and is there insider trading?

6.3yrs

Average board tenure


CEO

Ross MacDonald (61yo)

0yrs

Tenure

AU$476,917

Compensation

Dr. Ross Alexander MacDonald, Ph.D. serves as Member of Investment Committee at Uniseed Pty Limited and also serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (form ...


CEO Compensation Analysis

Compensation vs Market: Ross's total compensation ($USD323.84K) is about average for companies of similar size in the Australian market ($USD255.42K).

Compensation vs Earnings: Ross's compensation has been consistent with company performance over the past year.


Board Age and Tenure

6.3yrs

Average Tenure

59yo

Average Age

Experienced Board: CYP's board of directors are considered experienced (6.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.


Management Team

  • Ross MacDonald (61yo)

    MD, CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: AU$476.92k
  • Kilian Kelly

    Chief Operating Officer

    • Tenure: 0.5yrs
    • Compensation: AU$448.94k
  • Peter Webse (56yo)

    Company Secretary & Non-Executive Director

    • Tenure: 7.5yrs
    • Compensation: AU$100.42k

Board Members

  • Geoff Brooke (63yo)

    Independent Non-Executive Director

    • Tenure: 0.5yrs
    • Compensation: AU$52.27k
  • Paul Wotton (59yo)

    Non-Executive Chairman

    • Tenure: 2.8yrs
    • Compensation: AU$172.17k
  • Ross MacDonald (61yo)

    MD, CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: AU$476.92k
  • Stewart Washer (49yo)

    Non-Executive Director

    • Tenure: 6.3yrs
    • Compensation: AU$50.42k
  • Igor Slukvin

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Peter Webse (56yo)

    Company Secretary & Non-Executive Director

    • Tenure: 7.5yrs
    • Compensation: AU$100.42k

Company Information

Cynata Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cynata Therapeutics Limited
  • Ticker: CYP
  • Exchange: ASX
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$122.077m
  • Shares outstanding: 103.02m
  • Website: https://www.cynata.com

Location

  • Cynata Therapeutics Limited
  • 62 Lygon Street
  • Level 3
  • Carlton
  • Victoria
  • 3053
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2007
CYPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2007
CYYN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2007
51SDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2007

Biography

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Its l ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/22 10:36
End of Day Share Price2019/11/21 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.